Cargando…

In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model

BACKGROUND: CD101 is a novel, long acting echinocandin. The purpose of the study was to evaluate the PK/PD activity of CD101 against C. albicans (CA) and C. glabrata (CG) using the murine neutropenic disseminated candidiasis model. METHODS: 4 CA and 3 CG strains were used. MICs were determined by CL...

Descripción completa

Detalles Bibliográficos
Autores principales: Lepak, Alexander J, Zhao, Miao, Vanscoy, Brian, Ambrose, Paul G, Andes, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631110/
http://dx.doi.org/10.1093/ofid/ofx163.1224
_version_ 1783269371201716224
author Lepak, Alexander J
Zhao, Miao
Vanscoy, Brian
Ambrose, Paul G
Andes, David R
author_facet Lepak, Alexander J
Zhao, Miao
Vanscoy, Brian
Ambrose, Paul G
Andes, David R
author_sort Lepak, Alexander J
collection PubMed
description BACKGROUND: CD101 is a novel, long acting echinocandin. The purpose of the study was to evaluate the PK/PD activity of CD101 against C. albicans (CA) and C. glabrata (CG) using the murine neutropenic disseminated candidiasis model. METHODS: 4 CA and 3 CG strains were used. MICs were determined by CLSI standards. Single dose plasma PK was determined in groups of three mice after IP doses of 1, 4, 16, and 64 mg/kg. For treatment studies, mice were rendered neutropenic via administration of cyclophosphamide at days -4, -1, +2 and +4. Mice were infected with 6.3 ± 0.1 CFU/mL (CA) or 6.2 ± 0.2 CFU/mL (CG) injected into the lateral tail vein. Treatment dose range was 0.016 – 64 mg/kg, given once by IP injection 2 hours after infection. Experiment duration was 7 days at which point kidneys were aseptically harvested for CFU counts. The Emax Hill equation was used to model the dose–response data to PK/PD index AUC/MIC. The static and 1-log kill doses, as well as associated total and free AUC/MIC values were determined for each isolate. RESULTS: CD101 MICs were 0.008–0.06 mg/L for CA and 0.06 – 0.5 mg/L for CG. Single dose plasma PK parameter ranges include: Cmax 2.6–77 mg/L, AUC(0-∞) 93–4046 mg*hours/L, T(1/2) 28–41 hours. Dose-dependent cidal activity was observed with a maximal kill of over 2 log(10) CFU/kidney. Average 24 hours AUC over 7 days was used to model AUC/MIC data and fit the treatment response data well (CA R(2) 0.70, CG R(2) 0.86). The static dose (SD) and 1-log kill dose and associated total and free AUC/MIC values are shown (Table). CONCLUSION: CD101 demonstrated in vivo potency in the neutropenic murine disseminated candidiasis model against select CA and CG strains. Similar to studies with other echinocandins, AUC/MIC fit the exposure-response data well and CG targets were numerically lower than CA. However, while CA target range was similar, CG target range was almost 10-fold lower compared with other echinocandins. DISCLOSURES: B. Vanscoy, Cidara: Research Contractor, Research support; P. G. Ambrose, Cidara: Research Contractor, Research support; D. R. Andes, Cidara: Grant Investigator, Research support
format Online
Article
Text
id pubmed-5631110
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56311102017-11-07 In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model Lepak, Alexander J Zhao, Miao Vanscoy, Brian Ambrose, Paul G Andes, David R Open Forum Infect Dis Abstracts BACKGROUND: CD101 is a novel, long acting echinocandin. The purpose of the study was to evaluate the PK/PD activity of CD101 against C. albicans (CA) and C. glabrata (CG) using the murine neutropenic disseminated candidiasis model. METHODS: 4 CA and 3 CG strains were used. MICs were determined by CLSI standards. Single dose plasma PK was determined in groups of three mice after IP doses of 1, 4, 16, and 64 mg/kg. For treatment studies, mice were rendered neutropenic via administration of cyclophosphamide at days -4, -1, +2 and +4. Mice were infected with 6.3 ± 0.1 CFU/mL (CA) or 6.2 ± 0.2 CFU/mL (CG) injected into the lateral tail vein. Treatment dose range was 0.016 – 64 mg/kg, given once by IP injection 2 hours after infection. Experiment duration was 7 days at which point kidneys were aseptically harvested for CFU counts. The Emax Hill equation was used to model the dose–response data to PK/PD index AUC/MIC. The static and 1-log kill doses, as well as associated total and free AUC/MIC values were determined for each isolate. RESULTS: CD101 MICs were 0.008–0.06 mg/L for CA and 0.06 – 0.5 mg/L for CG. Single dose plasma PK parameter ranges include: Cmax 2.6–77 mg/L, AUC(0-∞) 93–4046 mg*hours/L, T(1/2) 28–41 hours. Dose-dependent cidal activity was observed with a maximal kill of over 2 log(10) CFU/kidney. Average 24 hours AUC over 7 days was used to model AUC/MIC data and fit the treatment response data well (CA R(2) 0.70, CG R(2) 0.86). The static dose (SD) and 1-log kill dose and associated total and free AUC/MIC values are shown (Table). CONCLUSION: CD101 demonstrated in vivo potency in the neutropenic murine disseminated candidiasis model against select CA and CG strains. Similar to studies with other echinocandins, AUC/MIC fit the exposure-response data well and CG targets were numerically lower than CA. However, while CA target range was similar, CG target range was almost 10-fold lower compared with other echinocandins. DISCLOSURES: B. Vanscoy, Cidara: Research Contractor, Research support; P. G. Ambrose, Cidara: Research Contractor, Research support; D. R. Andes, Cidara: Grant Investigator, Research support Oxford University Press 2017-10-04 /pmc/articles/PMC5631110/ http://dx.doi.org/10.1093/ofid/ofx163.1224 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Lepak, Alexander J
Zhao, Miao
Vanscoy, Brian
Ambrose, Paul G
Andes, David R
In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model
title In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model
title_full In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model
title_fullStr In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model
title_full_unstemmed In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model
title_short In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model
title_sort in vivo pharmacokinetic/pharmacodynamic (pk/pd) target characterization of the novel, long acting echinocandin cd101 against c. albicans and c. glabrata in the neutropenic murine disseminated candidiasis model
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631110/
http://dx.doi.org/10.1093/ofid/ofx163.1224
work_keys_str_mv AT lepakalexanderj invivopharmacokineticpharmacodynamicpkpdtargetcharacterizationofthenovellongactingechinocandincd101againstcalbicansandcglabrataintheneutropenicmurinedisseminatedcandidiasismodel
AT zhaomiao invivopharmacokineticpharmacodynamicpkpdtargetcharacterizationofthenovellongactingechinocandincd101againstcalbicansandcglabrataintheneutropenicmurinedisseminatedcandidiasismodel
AT vanscoybrian invivopharmacokineticpharmacodynamicpkpdtargetcharacterizationofthenovellongactingechinocandincd101againstcalbicansandcglabrataintheneutropenicmurinedisseminatedcandidiasismodel
AT ambrosepaulg invivopharmacokineticpharmacodynamicpkpdtargetcharacterizationofthenovellongactingechinocandincd101againstcalbicansandcglabrataintheneutropenicmurinedisseminatedcandidiasismodel
AT andesdavidr invivopharmacokineticpharmacodynamicpkpdtargetcharacterizationofthenovellongactingechinocandincd101againstcalbicansandcglabrataintheneutropenicmurinedisseminatedcandidiasismodel